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Summary
 
Staphylococcus epidermidis
 
 releases factors that activate the HIV-1 long terminal repeat, induce
cytokine release, and activate nuclear factor 
 
k
 
B in cells of macrophage lineage. The active ma-
terial had a mass of 34,500 daltons, was inactivated by proteases and partitioned into the phenol
layer on hot aqueous phenol extraction, and thus was termed phenol-soluble modulin (PSM).
High performance liquid chromatography (HPLC) of crude PSM yielded two peaks of activity
designated PSM peak 1 and peak 2. MALDI-TOF (matrix-assisted laser desorption ionization-
time of flight) mass spectroscopy indicated the presence of two components in peak 1, which
were designated PSM
 
a
 
 and PSM
 
b
 
. Peak 2 contained a single component, designated PSM
 
g
 
.
Separation of PSM
 
a
 
 and PSM
 
b
 
 in peak 1 could be achieved by a second HPLC procedure.
The structure of each component was determined by amino acid sequence analysis and identi-
fication and sequencing of their genes. PSM
 
a
 
, PSM
 
b
 
, and PSM
 
g
 
 were 22-, 44-, and 25-amino
acid, respectively, strongly hydrophobic polypeptides. PSM
 
g
 
 was identified as 
 
Staphylococcus
epidermidis
 
 delta toxin, whereas PSM
 
a
 
 and PSM
 
b
 
 exhibited more distant homology to previ-
ously described staphylococcal toxins. They appeared to exist as a complex or aggregate with
activity greater than the component parts. The properties of the 
 
S
 
.
 
 epidermidis
 
 PSMs suggest
that they may contribute to the systemic manifestations of Gram-positive sepsis.
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T
 
he systemic manifestations of sepsis are, in large part,
the result of cytokine production by host cells in re-
sponse to microbial products. The general term modulin
has been coined to describe these virulence factors (1, 2).
They include a variety of compounds of diverse structure
(2). The most studied and best characterized modulin is
LPS, which has been implicated in the development of the
shock-like state in Gram-negative sepsis through the in-
duction of cytokine production. However, the microbial
factors responsible for the induction of Gram-positive sepsis
have not been well characterized. Cell wall components
such as lipoteichoic acid (LTA)
 
1
 
 and peptidoglycan, as well
as certain exotoxins, have been implicated in some in-
stances. However, a more generally relevant, potent Gram-
positive modulin has yet to be identified (2).
We have recently reported that a factor or factors were
released by staphylococci that activated the HIV-1 LTR in
the transfected monocytic cell line THP-1 as measured by
the induction of luciferase synthesis (3). All of the 31 strains
of staphylococci tested (9 
 
S
 
.
 
 aureus
 
, 11 
 
S
 
.
 
 epidermidis
 
, 2 
 
S
 
.
 
hemolyticus
 
, 4 
 
S
 
.
 
 hominis
 
, 2 
 
S
 
.
 
 capitis
 
, 2 
 
S
 
.
 
 warneri
 
, and 1 
 
S
 
.
 
saprophyticus
 
) were active, although considerable variation
among strains was observed. The active components were
readily released by the staphylococci as indicated by their
presence in the overnight culture supernatant and in the
extracellular fluid after vigorous mixing of intact bacteria in
aqueous medium.
The HIV-1 LTR contains the promoter and enhancer
sequences required for the initiation of HIV-1 gene tran-
scription, including two binding sites for the transcription
factor nuclear factor 
 
k
 
B (NF-
 
k
 
B). NF-
 
k
 
B is released from
a cytoplasmic complex with an inhibitory protein I
 
k
 
B in
response to a variety of extracellular signals, and rapidly
translocates as homo- or heterodimers into the nucleus
where it activates a number of host defense–related genes
by binding to the DNA 
 
k
 
B consensus sequence (4, 5). We
report here that the staphylococcal product also activates
NF-
 
k
 
B in THP-1 cells and induces cytokine synthesis in
THP-1 cells and monocytes. This suggests that the induc-
 
1
 
Abbreviations used in this paper:
 
 LTA, lipoteichoic acid; MALDI-TOF,
matrix-assisted laser desorption ionization-time of flight; MWCO, mo-
lecular weight cut off; NEC, neonatal necrotizing enterocolitis; PSM,
phenol-soluble modulin; RLU, relative light units. 
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tion of luciferase synthesis in the transfected THP-1 cells
serves not only as a marker of the activation of the HIV-1
LTR in a cell of macrophage lineage, but also, in a broader
sense, as a marker of the activation of other host defense–
related genes dependent on NF-
 
k
 
B, such as genes involved
in cytokine production. The possibility that the staphylo-
coccal products may be important in the induction of the
systemic effects of Gram-positive sepsis prompted the puri-
fication of the factors released by 
 
S
 
.
 
 epidermidis
 
 and their
structural and functional characterization.
 
Materials and Methods
 
Special Reagents.
 
TAQ polymerase was from Boehringer-
Mannheim, radiolabeled 
 
g
 
-[
 
32
 
P]ATP was from New England
Nuclear, PMA, dimethylacetamide, DMSO, and polymyxin B
sulfate were from Sigma Chemical Co., human recombinant
TNF-
 
a
 
 was provided by Genentech, and neutralizing polyclonal
rabbit anti–human TNF-
 
a
 
 was from Genzyme Corp. LPS from
 
Escherichia coli
 
 055:B5 was obtained from List Biological Labs.,
Inc., and LTA from 
 
S. aureus
 
 was obtained from Sigma Chemical
Co. According to the suppliers, both the LPS and LTA were pre-
pared by hot, aqueous phenol extraction using modifications of
the methods of Westphal and Jann (6) and Fischer et al. (7), re-
spectively. The LPS preparation was reported by the manufac-
turer to contain 
 
,
 
1.7% protein.
 
Cells.
 
A stable transfectant of THP-1 cells (THP-1 LTR
 
luc
 
)
containing the luciferase reporter gene under the control of the
HIV-1 LTR was prepared as previously described (3). IG5, a Jur-
kat T cell–derived cell line containing a stably integrated HIV-1
luciferase construct (Jurkat LTR
 
luc
 
) (8) was obtained through the
Research and Reference Reagent Program, Division of AIDS,
NIAID, National Institutes of Health, Bethesda, MD. The HL-60
and U937 cell lines were obtained from the American Type Cul-
ture Collection. The cells were maintained in RPMI-1640 con-
taining 10 mM Hepes buffer, 2 mM 
 
l
 
-glutamine, 50 U/ml peni-
cillin, 50 mg/ml streptomycin sulfate, and 10% heat-inactivated
FBS (RF-10) (BioWhittaker). Human monocytes were isolated
from peripheral blood as previously described (9). Cell viability
was 
 
.
 
98% as determined by trypan blue exclusion. Monocytes (5 
 
3
 
10
 
5
 
) were added to each well of 24-well plates (Falcon 3847 Pri-
maria; Becton Dickinson) and allowed to adhere for 2 h. Nonad-
herent cells were removed by washing with PBS and the adher-
ent cells overlaid with RF-10 plus 10% heat-inactivated human
AB serum (BioWhittaker). The monolayer was incubated over-
night at 37
 
8
 
C in a CO
 
2
 
 incubator and just before use was washed
twice with RPMI without serum.
 
Activation of the HIV-1 LTR.
 
The components of the reac-
tion mixture were incubated at 37
 
8
 
C in a CO
 
2
 
 incubator (5%
CO
 
2
 
/95% air) for 6 h, and the luciferase activity was determined
as previously described (3) and designated as relative light units
(RLU). For studies with large numbers of samples, for example
column fractions with serial dilutions of each fraction, the reac-
tion was conducted in 96-well filter plates (MultiScreen GV;
Millipore) with the stimulus added to 2.5 
 
3 
 
10
 
5
 
 THP-1 LTR
 
luc
 
in a final volume of 250 
 
m
 
l RPMI. The cells were harvested,
rinsed, and lysed in the wells before determination of luciferase
activity as described above.
 
Isolation of Crude Phenol-soluble Modulin. S
 
.
 
 epidermidis 
 
UW-3
(University of Washington hospital strain 3; reference 3) was grown
overnight at 37
 
8
 
C with shaking in 10 liters of IMDM with Hepes
and 
 
l
 
-glutamine (BioWhittaker) that had been brought to 1%
 
glucose and filter-sterilized (0.22 
 
m
 
m Zap Cap; Schleicher and
Schuell). All subsequent steps were conducted at 4
 
8
 
C except as
noted. The bacteria were removed by centrifugation (6000 
 
g
 
, 30
min) and filtration, and the supernatant was concentrated by tan-
gential (Prep/Scale CDUF 02.5LB; Millipore) and centrifugal
(Centriprep 10; Amicon) ultrafiltration to 
 
z
 
20 ml. The prepara-
tion was dialyzed extensively against 0.4 M NaCl in 25 kD mol wt
cutoff (MWCO) tubing (Spectra/Por CE; Spectrum) and then
against distilled water in 12 kD MWCO tubing (Sigma Chemical
Co.). 50 ml of buffer-saturated phenol (GIBCO BRL) and enough
1 M sodium acetate (pH 4.7) was added to the retentate to bring
the aqueous portion to 0.1 M. The mixture was maintained as a
single phase by raising the temperature to 65
 
8
 
C and agitated for 1 h.
After cooling and centrifugation for 15 min, the phenol layer was
removed and the aqueous layer was extracted twice more with 25
ml of phenol. The pooled phenol layers were extensively dialyzed
against distilled water at 4
 
8
 
C in 12 kD MWCO tubing. A fine pre-
cipitate formed which was vigorously mixed into the aqueous re-
tentate. This material, designated phenol-soluble modulin (PSM),
was lyophilized and stored at 
 
2
 
20
 
8
 
C.
 
Chromatography.
 
Gel chromatography was performed to de-
termine size using a fast protein liquid chromatography apparatus
and an HR 10/30 Superose 12 column (Pharmacia). After equili-
brating the column in PBS, 100 
 
m
 
l of concentrated bacterial su-
pernatant or 100 
 
m
 
g of phenol-extracted material was injected
and subsequently eluted with PBS at 0.4 ml/min. 2-ml fractions
were collected and assayed. Molecular weight was estimated by
comparing the elution time of standard proteins to the elution
time of active fractions, as per manufacturer’s instructions.
HPLC was performed on an LKB (now Pharmacia) 2150 in-
strument equipped with a Vydak 0.46 
 
3 
 
15 cm C4 column and a
flow cell detector measuring absorbance at 214 nm. For the rapid
(10 min) HPLC procedure, a 10 min gradient was run from 36 to
100% 1-propanol, and the aqueous portion was buffered with 2.5
mM ammonium acetate, pH 6.7. 100 
 
m
 
g of dialyzed, lyophilized
PSM was injected in 20 
 
m
 
l 20% 1-propanol, and fractions were
collected, lyophilized, and frozen. Slow (57 min) HPLC was
done on pooled peak 1 material from several rapid HPLCs with a
gradient from 28 to 48% 1-propanol, buffered as above. Slow (57
min) HPLC of crude material was done similarly except that the
gradient was from 25 to 45% 1-propanol. For assay, the lyoph-
ilized material was dissolved in PBS with vigorous vortexing, and
dilutions of these fractions were compared with a standard curve
made from material that was similarly processed (in terms of lyoph-
ilization and solvent exposure) but not subjected to the HPLC
separation.
 
Chemical Analysis of PSM
 
a
 
, PSM
 
b
 
, and PSM
 
g
 
.
 
Endotoxin was
measured by a Limulus Amebocyte Lysate kit (BioWhittaker).
Total phosphorous content after ashing of the specimen was de-
termined by the ascorbic acid/ammonium molybdate method
(10). Amino acid composition was done by AAA Laboratory on a
Beckman 7300 Analyzer after 20 h of hydrolysis in 6 N HCl,
0.05% mercaptoethanol, and 0.02% phenol at 115
 
8
 
C. Mass spec-
trometry and NH
 
2
 
-terminal sequencing was performed by the
University of Washington Biochemistry Core Facility. Mass
spectral ionization was via MALDI-TOF (matrix-assisted laser
desorption ionization–time of flight) on a Voyager Elite (PerSep-
tive Biosystems) instrument. Sequencing was done by Edman
degradation on an Applied Biosystems 470A sequencer with on-
line 120A phenol-thio-hydantoin analyzer. COOH-terminal se-
quencing was performed by partial digestion with carboxypepti-
dase Y and subsequent mass spectrometry, as previously described
(11). Peak 1 from the rapid HPLC (see above) was rechromato- 
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graphed using acetonitrile/0.05% TFA in a second, rapid HPLC,
and the single peak was submitted to the Harvard Microchemis-
try Facility (Cambridge, MA) for tryptic digestion, separation of
the fragments by HPLC, and sequencing of the fragments by Ed-
man degradation. Fragment sequences were confirmed by mass
spectrometry using a Finnigan TSQ Triple Quadrupole Mass
Spectrometer. Sequence alignment was performed using the Ba-
sic Local Alignment Search Tool (BLAST).
SDS-PAGE was performed using a 12.5% gel and stained for
protein with silver stain and Coomassie blue and for polysaccha-
ride with Alcian blue–silver (12). High percentage tricine gels
(16%) used the method of Schagger and von Jagow (13) and had
a stacking gel of 12% and a resolving gel of 16%. Gels were fixed
with 20% TCA.
Proteinase digestion of PSM was performed using proteinases
immobilized on beaded agarose (proteinase K, 
 
Streptomyces griseus
 
protease, trypsin [Sigma Chemical Co.]). Beads were washed
three times with PBS and resuspended in 1 ml PBS containing
20 
 
m
 
g PSM. After incubation for 3 h at 37
 
8
 
C with agitation, the
proteinases were removed by low speed (325 
 
g
 
) centrifugation
and the supernatant was tested for its ability to activate the HIV-1
LTR in THP-1 cells.
 
Cytokine Production.
 
HL-60, U937, THP-1 (THP-1 LTR
 
luc
 
),
and human monocytes were incubated with LPS, LTA, and the
PSM preparations, as described in the figure legends, for 6 h, and
the supernatant fluid collected and frozen at 
 
2
 
20
 
8
 
C. At intervals
the samples were thawed and TNF-
 
a
 
, IL-1
 
b
 
, and IL-6 levels
were determined using commercially available ELISA kits (TNF-
 
a
 
,
Endogen; IL-1
 
b
 
, Genzyme; IL-6, Immunotech).
Electrophoretic Mobility Shift Assay. The nuclear extraction
protocol is essentially that of Dignam et al. (14) as modified by
Brophy et al. (15). For the preparation of nuclear extracts, 107
THP-1 LTRluc were incubated with 100 ng/ml PSM, PSM peak
1, or PSM peak 2 in RPMI at a final volume of 2.0 ml for 1 h at
378C in 5% CO2/95% air. The protein concentration of the ex-
tracts was determined using the Bradford assay (Bio-Rad). The
extracts were stored in aliquots at 2708C until use. The double
stranded  kB consensus oligonucleotide (59-AGT TGA GGG
GAC TTT CCC AGG C-39), obtained from Promega, was end-
labeled with g-[32P]ATP and T4 polynucleotide kinase using the
Promega Gel Shift Assay kit. For supershifts, 1 ml of NF-kB p65
rabbit antiserum (provided by Dr. Karol Bomsztyk, University of
Washington, Seattle, WA), 4 ml (4 mg) of NF-kB p50 rabbit
polyclonal IgG antibody (Santa Cruz Biotechnology), or 2 ml (2 mg)
of NF-kB c-Rel rabbit polyclonal IgG antibody (Santa Cruz Bio-
technology) were preincubated with the nuclear extracts in bind-
ing buffer for 30 min before addition of the labeled probe. For
studies with cold probe, 503 cold probe was added at the time of
addition of the labeled probe. Electrophoresis of the DNA-pro-
tein complexes was performed with 6% nondenaturing polyacryl-
amide gels as described in the Promega Gel Shift Assay System
protocol.
Genetic Analysis. S. epidermidis UW-3 DNA was obtained by
incubating the bacteria with 50 mg/ml lysostaphin (Sigma Chem-
ical Co.) for 2 h at 378C and then using the standard isolation
procedure for Gram-negative bacteria (16). Southern blots of ge-
nomic DNA digested with an array of restriction endonucleases
were probed with radiolabeled, degenerate oligonucleotides
based on Edman degradation data (17). Plasmids were isolated us-
ing a Quiagen kit, and sequencing was done by fluorescent dye
termination on an ABI Prism Model 377 at the University of
Washington Biochemistry Facility using ABI (Perkin-Elmer)
dRhodamine or BigDye kits. The genetic sequence downstream
of each PSM gene was obtained by anchor PCR (18, 19). PCR
was performed using established procedures (20) with an Eppen-
dorf MicroCycler. All PCR was done with a 948C presoak for
4 min and a final extension step at 558C for 9.5 min, and, except
where noted, used 35 cycles of 15 s at 948C, 15 s at 558C, and 90 s
at 728C. A “doubled” PCR is one in which 1 ml from a com-
pleted PCR reaction is used as template in an identical PCR re-
action.
The anchor PCR for PSMa incorporated a single-strand ex-
tension and Exonuclease III digestion as previously described (21)
except that the final PCR was doubled. Sequence obtained in
this manner generated the primers for direct PCR of PSMa (up-
stream: 59-CGA ATA ATA CTA TTA ATA TAT TTT AAA
TGA GCA AGA GTG TCA ATG G) (downstream: 59-CAT
GGT TGT AAA ACA TAT AAA AAT GCT AAT GAG TGT
GAC AAT AAT TGA TGA TAA ACT GG).
Anchor PCR for PSMb revealed that the gene occurred as
two copies with z50 bases in between. A size-selected (5 kB) li-
brary of EcoRV cut genomic DNA in pBS was screened via col-
ony hybridization to an oligomer specific for this PSMb inter-
genic region (59-TCT TAG TTT TTT AAA ATA TAA ATT
TAA ATA ATT AAT TAG GGA GAG ATA) as well as two de-
generate oligomers based on the amino acid sequence. Positive
colonies were picked, grown out, and sequenced.
Anchor PCR for PSMg yielded z500 bases of downstream
sequence. From this sequence was generated reverse (59-TGC
TTC TCA CTT GCT TAG TTT ATA TTA GTA AAT TAT
TAA GTT GGG ATG GCT CAA CAA CTC) and forward (59-
TTT GCT AGT AAC TGT AGT TTC CTT GGA CTC AGT
GTT ACG TAT TAT TCT TAG CTA CCT TAA) primers for
inverse PCR (22) on a Sau 3AI digested template. This inverse
PCR provided sequence for the creation of upstream (59-GAT
ATT TTA CCA TAT TTA GTT TTA CAG TTG AGT ACT
AAA TAT TGC TAT) and downstream (59-CCA CAT CTT
TAT AAA TAG CAT AGT TAA AGC CGT GAG C) primers
for directly amplifying PSMg.
To compensate for errors introduced by TAQ, the sequences
of several direct PCR products using primers for PSMa and for
PSMg were compared, and at least three identical assignments
were found for each nucleotide in the sequence shown. The gene
for PSMb was isolated as two identical, 5-kB recombinant clones
sequenced in their entirety.
Statistical Analyses. The results are presented as the mean 6
SEM. The Mann-Whitney U rank-sum test (unpaired, two-
tailed) was used to analyze differences for significance unless oth-
erwise indicated. P . 0.05 was considered not significant.
Results
S. epidermidis PSM. S. epidermidis strain UW-3 was
grown overnight in glucose-enriched IMDM with Hepes
and l-glutamine. This medium supported the rapid growth
of the organism and, being a defined medium lacking large
mol wt components (.3.5 kD), could be subsequently re-
moved by dialysis. The culture medium, free of micro-
organisms, was concentrated z500-fold and dialyzed. About
half the activity was lost if dialysis was carried out with
25 kD MWCO tubing against distilled water; these losses
were prevented by dialysis against 0.4 M NaCl. A two-step
dialysis program was therefore used, with 25 kD MWCO
tubing in 0.4 M NaCl followed by 12 kD MWCO tubing910 Staphylococcus epidermidis Inflammatory Polypeptide Complex
in distilled water. Dialysis suggested a mol wt for the active
material of .25,000 daltons and this was supported by gel
chromatography using a Superose 12 column which indi-
cated an effective mass for the concentrated and dialyzed
material of 34,500 6 5,900 daltons (mean 6 SD, n 5 3)
Hot aqueous phenol extraction was performed as used in
the purification of LPS (6) and LTA (7). In contrast to LPS
and LTA, which partition into the aqueous layer, the S.
epidermidis factor was found to be entirely in the phenol
layer, thus the term phenol-soluble modulin (PSM). The
mass of the active material, as measured by Superose 12
chromatography, remained z35 kD, allowing the phenol
to be removed by dialysis. However, MALDI-TOF mass
spectroscopy of the PSM did not reveal any component in
the 35 kD region, but rather indicated the presence of four
low mol wt components of 2,489, 2,648, 2,849, and 4,668
daltons (M 1 I) (Fig. 1). The recovery of activity in two
large scale purifications, beginning with 10 liters of culture
medium and proceeding through concentration, dialysis,
and three phenol extractions was 190% (wt 74.8 mg) for
preparation A and 87% (wt 230 mg) for preparation B. In
five smaller scale purifications using 500 ml of culture me-
dium and a single phenol extraction, recovery was 71 6 29%
(mean 6 SD). The total amount of material was determined
by weight after dialysis and lyophilization, and the recovery
was determined by comparing the activity of a weighed sam-
ple of the product to that of the starting material.
The S. epidermidis PSM had a small but significant acti-
vating effect on the HIV-1 LTR in THP-1 cells at 1 ng/ml
with the activation increasing to a maximum at 30 ng/ml
and remaining high as the PSM concentration was increased
to 1 mg/ml (Fig. 2). PSM was routinely used at 100 ng/ml.
In contrast to PSM, LPS did not activate the HIV-1 LTR in
THP-1 cells at comparable concentrations; however, a small
but significant activation was observed at 10 and 100 mg/ml.
LTA from S. aureus was ineffective over the entire concen-
tration range used. In contrast to the LTR in THP cells, the
HIV-1 LTR introduced into Jurkat T cells in association
with the luciferase reporter gene was unaffected by PSM as
well as by LPS and LTA under comparable conditions. The
background luciferase activity (29,379 6 6,538, n 5 4) re-
mained unchanged on the addition of 0.001–1 mg/ml PSM
or 0.01–100 mg/ml LPS or LTA.
The activation of the HIV-1 LTR in THP-1 cells by the
S. epidermidis PSM was not due to the release of TNF-a,
since blocking antibody to TNF-a (diluted 1:2,000), al-
though it inhibited activation via exogenously added TNF-a
(100 U/ml), did not affect activation by PSM (100 ng/ml)
(background, 1,189 6 509 [RLU 6 SEM]; PSM, 363,987 6
Figure 1. MALDI-TOF mass spectroscopy of S. epidermidis PSM. The
large box has a range of 500–50,500 m/z and the insert is a magnification
of the 2,000–5,000 m/z range. The designated masses are M11 (H).
Figure 2. Activation of the
HIV-1 LTR in THP-1 cells by
PSM, LPS, and LTA. The re-
action mixture contained 2 3
106 THP-1 LTRluc and PSM,
LPS, or LTA at the concentra-
tions indicated in RPMI at a
final volume of 2.0 ml. The
y-axis was broken to allow for
an increased scale in the lower
range to illustrate the signifi-
cant effect of high concentra-
tions of LPS. The results are the
mean 6 SEM of 4–13 experiments, with the asterisk indicating a signifi-
cant difference from no stimulant (P , 0.05).
Figure 3. Effect of heat and proteinases on PSM activity. (A) PSM at
10 mg/ml in RPMI was heated in a boiling water bath for the periods in-
dicated. For determination of luciferase synthesis, the reaction mixtures
contained 2 3 106 THP-1 LTRluc, either unheated or heated PSM at 100
ng/ml, and RPMI at a final volume of 2.0 ml. The results are the mean
(2 background) 6 SEM of four experiments. The asterisk indicates a
significant difference from unheated PSM. (B) PSM was preincubated
with immobilized proteinase (proteinase K, Streptomyces griseus protease,
trypsin) as described under Materials and Methods and activation of the
LTR compared with that produced by untreated PSM or PSM preincu-
bated with agarose beads without bound proteinase. The results are the
mean 6 SEM of three experiments. The asterisk indicates a significant
difference from PSM alone (P , 0.05, unpaired Student’s t test).911 Mehlin et al.
95,583; PSM 1 anti–TNF-a antibody, 429,532 6 105,532,
NS versus PSM alone; TNF-a, 15,048 6 5,585; TNF-a 1
anti–TNF-a antibody, 2,278 6 332, P , 0.05 versus TNF-a
alone; n 5 4). The low activity of TNF-a as compared with
PSM further supported the absence of an association.
The S. epidermidis PSM was heat resistant, requiring 15 min
at 1008C for a partial loss of activity and 60–120 min for
complete loss of activity (Fig. 3 A). Exposure to three different
proteinases (proteinase K, Streptomyces griseus protease, trypsin)
immobilized on agarose beads resulted in a loss of activity
(Fig. 3 B), suggesting that the active material is proteinaceous.
S. epidermidis PSM Peak 1 and Peak 2. Separation of PSM
by HPLC with a C4 column, a 36–100% 1-propanol gradi-
ent, an elution rate of 1 ml/min, and an elution time of 10
min yielded two peaks of activity in the THP-1 LTRluc
assay, which were designated PSM peak 1 and peak 2 (Fig.
4 A). Peak 1 had a lower absorbance at 214 nm but consider-
ably more activity than peak 2. Approximately 25% of the
activity applied to the column was recovered. Neither active
peak contained phosphorous as assessed by a modified Fiske-
Subborow assay. SDS-PAGE of each peak revealed a band
that ran at the dye front even with high percentage tricine
gels that could resolve down to 6 kD. These low mol wt
bands stained positively for protein with Coomassie blue and
silver stains. Silver staining was not intensified by Alcian blue
pretreatment, suggesting the absence of polysaccharide.
The effect of PSM, PSM peak 1, and PSM peak 2 on
THP-1 cells was not limited to the activation of the HIV-1
LTR. Fig. 5 demonstrates the stimulatory effect of 100 ng/ml
PSM, PSM peak 1, and, to a lesser degree, PSM peak 2 on
Figure 4. HPLC separation. The upper section of each segment indi-
cates the absorbance at 214 nm (solid line) and the 1-propanol gradient
(broken line). The lower section indicates the activity of the fractions in
the THP-1 LTRluc assay. (A) Rapid HPLC of crude PSM: C4 column;
36–100%, 10 min, 1-propanol gradient; elution rate 1 ml/min. (B) HPLC
of peak 1 from A above: C4 column; 25–45%, 57 min, 1-propanol gradi-
ent; elution rate 1 ml/min. (C) Slow HPLC of crude PSM: C4 column;
28–48%, 57 min, 1-propanol gradient; elution rate 1 ml/min.
Figure 5. Effect of LPS, LTA, PSM, PSM peak 1, and PSM peak 2 on
cytokine production by THP-1 cells and human monocytes. With THP-1
cells, the reaction mixture contained 2 3 106 THP-1 cells, and where
indicated 100 ng/ml LPS, LTA, PSM, PSM peak 1, or PSM peak 2 in
RPMI at a final volume of 2.0 ml. With monocytes, 100 ng/ml LPS,
LTA, PSM, PSM peak 1, or PSM peak 2 were added to a monolayer of
5 3 105 monocytes in 1.0 ml of RPMI. TNF-a, IL-1b, and IL-6 levels
were determined as described in Materials and Methods. The results are
the mean 6 SEM of four to six experiments. The asterisk and plus sign
indicate a significant difference from no stimulant (none) by the unpaired
and paired Mann-Whitney U tests, respectively.912 Staphylococcus epidermidis Inflammatory Polypeptide Complex
TNF-a and IL-1b production by THP-1 cells. Little IL-6
was produced by untreated THP-1 cells, with PSM produc-
ing a small but significant increase by paired analysis. As with
activation of the HIV-1 LTR, LPS or LTA had no effect on
the production of these cytokines by THP-1 cells. In con-
trast to its effect on THP-1 cells, PSM as well as LPS and
LTA did not induce TNF-a production by HL-60 (cells
alone, 32 6 23; LPS, 17 6 10; LTA, 17 6 10; PSM, 15 6
15 pg/ml; n 5 4, NS) or U937 cells (cells alone, 14 6 8;
LPS, 11 6 7; LTA, 11 6 6; PSM, 9 6 9 pg/ml; n 5 4, NS).
TNF-a, IL-1b, and IL-6 production by human mono-
cytes also was stimulated by PSM, PSM peak 1, and, to a
lesser degree, PSM peak 2 (Fig. 5). In contrast to THP-1
cells, LPS and LTA also induced cytokine production by
monocytes, although LTA did not affect monocytic pro-
duction of IL-1b. PSM was less effective than LPS, but
more effective than LTA as a stimulant of TNF-a produc-
tion by monocytes (Fig. 6). A significant effect of LPS was
observed at concentrations down to 0.1 ng/ml with the ef-
fect at 0.01 ng/ml just not significant by the Mann-Whitney
U test (P 5 0.07), and just significant by the Student’s t test
(P 5 0.04). PSM was effective at concentrations down to 10
ng/ml, whereas LTA was stimulatory only at 100 ng/ml.
The passage of PSM into the phenol layer upon hot phe-
nol extraction and the low activity of LPS or LTA suggests
that the activation of the HIV-LTR in THP-1 cells by
PSM is not due to the presence of LPS or LTA. Further
evidence against LPS or LTA involvement was the absence
of inhibition by polymyxin B. Polymyxin B alone at 1 mg/ml
had no effect on the LTR in THP-1 cells (background,
1,088 6 154 [RLU 6 SEM]; polymyxin B, 1,388 6 320;
n 5 4, NS), nor did it decrease the activation by 100 ng/ml
PSM (PSM, 243,012 6 29,691; PSM 1 polymyxin B,
259,048 6 27,766; n 5 4, NS). Polymyxin B at 1 mg/ml
also had no effect on TNF-a production by monocytes in-
duced by 100 ng/ml PSM, whereas strongly inhibiting
production by 100 ng/ml LPS or LTA (PSM without pol-
ymyxin B, 2,781 6 997 pg/ml; with polymyxin B, 2,070 6
779; n 5 5-6, NS; LPS without polymyxin B, 3,160 6
1,074; with polymyxin B, 358 6 140; n 5 5-6, P , 0.005;
LTA without polymyxin B, 1,088 6 421; with polymyxin
B, 88 6 71; n 5 5-6, P , 0.05). The endotoxin level of a
reaction mixture containing 100 ng/ml of PSM in RPMI
was below the level of detection (,1 pg/ml) by the Limu-
lus Amebocyte Lysate assay.
Both the HIV-1 LTR and the promoter region of the
cytokine genes contain binding sites for the transcription
factor NF-kB. The activation of NF-kB in THP-1 cells by
S. epidermidis PSM, PSM peak 1, and PSM peak 2, as deter-
mined by the electrophoretic mobility shift assay, is shown
in Fig. 7. Nuclear extracts obtained from THP-1 cells pre-
treated with PSM, PSM peak 1, and PSM peak 2 produced
a retardation in the migration of the 32P-labeled kB con-
sensus oligonucleotide, which was not seen when extracts
from untreated THP-1 cells were used. Antibodies to the
NF-kB components p65 and p50 caused a further retarda-
tion in migration (supershift) whereas antibody to c-Rel
had no effect. The specificity of the mobility shift assay for
NF-kB was further supported by competition studies in
which unlabeled NF-kB oligonucleotide prevented the ap-
pearance of the retarded band.
S. epidermidis PSMa, PSMb, and PSMg. MALDI-TOF
mass spectroscopy of PSM peak 1 revealed two compo-
nents, a minor component with a mass of 2,503.8 daltons
(designated PSMa) and a major component of 4,683.8 dal-
tons (designated PSMb), whereas mass spectroscopy of
PSM peak 2 indicated a single component with a mass of
2,864.8 daltons (designated PSMg). The two components
in PSM peak 1 could be separated by a second, slow HPLC
procedure using the same column and solvents but a
longer, shallower gradient (Fig. 4 B). The composition of
these peaks was verified by mass spectrometry. It was ob-
served that the second slow HPLC of peak 1 resulted in a
considerable loss of activity; ,5% of the activity applied
would typically be recovered. In every instance, PSMa was
more active than PSMb and in some instances PSMb was
inactive. A single HPLC separation of the S. epidermidis
PSM using a slow HPLC yielded three major peaks of 214
nm-absorbing material (Fig. 4 C). The first peak, PSMa by
mass spectrometry, contained most of the activity. The two
later peaks were not completely separated from each other.
Mass spectroscopy indicated that the peak eluting at 29–31
min contained PSMb as its major component and that the
peak eluting at 31–33 min was largely PSMg. The luci-
Figure 6. Dose response of
PSM, LPS, and LTA on TNF-a
production by human blood
monocytes. We added PSM,
LPS, and LTA at the concentra-
tions indicated, and RPMI at a
final volume of 1.0 ml, to mono-
layers containing 5 3 105 mono-
cytes. After incubation for 6 h,
the supernatant fluid was re-
moved for the determination of
TNF-a levels. The results are
the mean 6 SEM of three to
eight experiments. The asterisk
indicates a significant difference
from background (P , 0.05).
Figure 7. Activation of NF-kB
in THP-1 cells by PSM. The
lanes from left to right are: 1,
probe alone; 2, nuclear extract
from untreated THP-1 cells; 3,
nuclear extract from PSM-
treated THP-1 cells alone; 4, nu-
clear extract from PSM-treated
THP-1 cells with anti-p65 anti-
body; 5, nuclear extract from
PSM-treated THP-1 cells with
anti-p50 antibody; 6, nuclear ex-
tract from PSM-treated THP-1
cells with anti–c-Rel antibody;
7, nuclear extract from PSM-treated THP-1 cells with 103 cold probe;
8, nuclear extract from peak 1–treated THP-1 cells; and 9, nuclear extract
from peak 2–treated THP-1 cells.913 Mehlin et al.
ferase assay indicated a single peak of activity that over-
lapped both of these later peaks.
Amino Acid Sequence Analyses. PSMa derived from the
single, slow (57 min) HPLC separation using the 28–48%
1-propanol gradient was subjected to Edman degradation,
which revealed the NH2-terminal 11 amino acids. Edman
degradation of peak 1 provided the NH2-terminal 24
amino acids of PSMb. PSMa was present in peak 1 in rela-
tively small amounts that did not interfere with the se-
quencing of PSMb. The complete sequence of PSMa and
PSMb was determined by NH2-terminal Edman degrada-
tion of tryptic digests. No fragments were found that did
not correspond to PSMa or PSMb. Verification of the
COOH-terminal 8 amino acids of PSMb was obtained by
carboxypeptidase Y digestion and sequential mass spectros-
copy. PSM peak 2 was used for the derivation of the NH2-
terminal 16 amino acids of PSMg.
Genetic Characterization of PSMa, PSMb, and PSMg. The
amino acid sequence enabled the creation of degenerate
oligonucleotides and the isolation of the genes for the three
PSMs. Anchor PCR allowed for the determination of
sequence downstream from each gene. The isolation of
the entire gene resulted from additional anchor PCR (for
PSMa), colony hybridization (for PSMb), and inverse
PCR (for PSMg). Although PSMb could be readily cloned
in E. coli, PSMa and PSMg could not, so the gene se-
quence for these two was determined via several directly
sequenced PCRs. All coding regions were preceded by a
putative Shine-Delgarno sequence and followed by a stop
codon. The deduced amino acid sequence was in agree-
ment with that found by Edman degradation and was con-
sistent with amino acid analysis.
PSMa is a 22-amino acid polypeptide without a high
degree of homology to any known protein, although some
similarity to delta toxin is evident (Fig. 8). PSMb is a 44-
amino acid polypeptide (Fig. 9) whose gene was found to
exist in two copies with an intervening 58 nucleotides. The
deduced amino acid sequence for the two copies was iden-
tical, although slight codon variation was noted. Homology
to S. hemolyticus antigonococcal polypeptides 1, 2, and 3, and
S. lugdunensis SLUSH polypeptides A, B, and C is shown.
PSMg is a 25-amino acid polypeptide with the sequence
MAADIISTIGDLVKWIIDTVNKFKK, which is identi-
cal to that of S. epidermidis delta toxin (23). The gene se-
quence of PSMg with 100 flanking bases was identical to
that reported by Otto et al. (24) except for two base differ-
ences in the flanking regions (Fig. 10).
The mass of PSMa, PSMb, and PSMg calculated from
the amino acid sequence was 2,460.0, 4,639.3, and
2,820.4, respectively. Mass spectrometry of PSM before
HPLC indicated the presence of components of mass
2,487.9, 4,667.2, and 2,848.5, which exceeded the calcu-
lated mass of PSMa, PSMb, and PSMg by z28 daltons in
Figure 8. PSMa. (A) The complete amino acid and genomic squence
with 100 flanking bases is shown. (B) Alignment of PSMa and delta toxin
(PSMg). Identical residues are designated as dots, and each polypeptide
has a single gap to facilitate alignment.
Figure 9. PSMb. (A) The complete amino acid and gene sequence for
both copies is shown along with the intergenic sequence and 100 bases of
flanking sequence. The deduced amino acid sequence is the same for the
two genes and there is a high degree of homology in the genetic sequence 30
bases upstream of each copy. (B) Homology between PSMb and S. hemo-
lyticus antigonococcal proteins 1, 2, and 3 and S. lugdunensis SLUSH pro-
teins A, B, and C.
Figure 10. PSMg. The complete amino acid and genomic sequence
with 100 flanking bases is shown. Base differences from the published se-
quence (24) are underlined.914 Staphylococcus epidermidis Inflammatory Polypeptide Complex
each instance, a difference compatible with formylation of
the polypeptides. After HPLC, the mass of each PSM was
further increased by 16 daltons, consistent with the oxida-
tion of methionine. A fourth component of 2648.0 daltons
found at low levels in the postphenol extraction PSM was
not detected on the subsequent HPLC separations.
The gene sequence data, including 100 bases of flanking
sequence, for PSMa, PSMb, and PSMg, are available from
EMBL/GenBank/DDBJ under accession numbers AF068632,
AF068633, and AF068634, respectively.
Discussion
We describe here modulins from S. epidermidis that parti-
tion into the phenol layer on hot aqueous phenol extrac-
tion. A number of lines of evidence indicate that the active
components were neither LPS nor LTA. Both LPS and
LTA partition into the aqueous layer on hot phenol extrac-
tion, whereas PSM partitioned into the phenol layer. LTA
from S. aureus did not activate the HIV-1 LTR in THP-1
cells at concentrations up to 100 mg/ml and List E. coli
055:B5 LPS was only weakly active requiring concentra-
tions of 10–100 mg/ml. In contrast, PSM was active at
concentrations down to 1 ng/ml. Furthermore, polymyxin
B, which binds to and inactivates LPS and LTA, had no ef-
fect on the activation of the HIV-1 LTR in THP-1 cells
nor did it inhibit TNF-a production in monocytes in-
duced by PSM. In contrast, polymyxin B strongly inhibited
LPS- or LTA-induced production of TNF-a by mono-
cytes. Active material also was devoid of sugars and phos-
phorous, and proteinase inactivation suggested that it was a
protein or polypeptide. Finally, LPS could not be detected
in the PSM preparation.
The S. epidermidis PSM could be separated into three ac-
tive polypeptides, designated PSMa, PSMb, and PSMg.
PSMa is a 22-amino acid polypeptide whose amino acid
sequence shows 40% identity to S. epidermidis delta toxin
when a single residue gap is placed in each polypeptide
(Fig. 8 B). PSMb is a 44-amino acid polypeptide with con-
siderable structural homology to previously described
gonococcal inhibitor 1, 2, and 3 from S. hemolyticus (25)
and to a lesser degree to three structurally related peptides
from  S. lugdunensis with synergistic hemolytic activity
(SLUSH A, B, and C) (26) (Fig. 9 B). Closest homology
was to S. hemolyticus gonococcal inhibitor 2 (73% identity).
The polypeptides from the three staphylococcal strains had
in common similar molecular weights (S. epidermidis and S.
hemolyticus, 44 amino acids; S. lugdunensis, 43 amino acids),
strong hydrophobicity, and the absence of arginine, cys-
teine, histidine, proline, and tyrosine. It has been proposed
on the basis of its primary structure that the S. hemolyticus
antigonococcal proteins are signal sequences for secreted or
membrane-associated proteins (25). Antibody to the S. hemo-
lyticus polypeptides recognized a 51-kD protein in the cy-
toplasmic fraction of S. hemolyticus, and it was proposed that
this protein may contain a signal peptide with homology to
the S. hemolyticus antigonococcal proteins (27). As all three
S. epidermidis PSMs have a stop codon immediately after
their COOH terminus, such a role is unlikely for these
molecules. Two copies of the gene for PSMb were de-
tected. PSMg is identical to delta toxin of S. epidermidis
(23). Delta toxin from S. epidermidis consists of 25 amino
acids that share a high degree of homology with delta toxin
from S. aureus. The latter consists of 26 amino acids with
the substitution of glutamine for alanine at position 3 and
the presence of threonine at position 24 which was absent
in the S. epidermidis toxin (28). S. aureus delta toxin (delta
hemolysin) is an amphipathic, helical peptide which can in-
sert into hydrophobic membranes to form cation-selective
ion channels with each channel consisting of six delta toxin
alpha helices oriented with their hydrophilic face lining a
central aqueous pore (29–33). Under some experimental
conditions, lysis of the cell can occur. Helical wheel analy-
sis of PSMa also suggests its orientation as an amphipathic
alpha helix, with hydrophobic amino acids on one face and
hydrophilic amino acids on the other.
PSMa, PSMb, and PSMg are all strongly hydrophobic
polypeptides that lack arginine, cysteine, histidine, proline,
and tyrosine. Two (PSMa and PSMg) have some structural
homology to each other. Based upon their absorption at
214 nm and normalized for molecular weight, the three
components occur in a molar ratio of z1:2:5 PSMa/
PSMb/PSMg. Their low molecular weight confirms the
findings with SDS-PAGE and MALDI-TOF mass spec-
troscopy which indicated mol wt ,5 kD. However, sepha-
dex gel chromatography either of the crude extract or the
S. epidermidis PSM suggested an active product with mol wt
z35 kD, which is consistent with its retention during dial-
ysis and ultrafiltration. Both S. aureus delta toxin (34, 35)
and S. hemolyticus gonococcal growth inhibitor (36) have
been reported to form complexes or aggregates of various
sizes and similar aggregation or complexing of S. epidermidis
PSM appears to occur as well. It is not clear whether the
polypeptides assemble into a highly ordered complex or
whether they aggregate due to hydrophobic interactions with
little or no order. We do not know the degree to which each
polypeptide participates in the aggregate nor whether other
components, proteinaceous or not, also are involved.
Although our routine assay for the S. epidermidis PSMs is
the activation of the HIV-1 LTR in THP-1 cells, their ef-
fects are not limited to this reaction or to this cell type. Cy-
tokine production (TNF-a, IL-1b, IL-6) by either THP-1
cells or peripheral blood monocytes also is increased, as is
the activation of NF-kB in THP-1 cells. Both the HIV-1
LTR and the cytokine genes contain NF-kB binding sites
in their promoter region, suggesting that activation of
NF-kB by the S. epidermidis PSMs may be central to the
other effects observed. Cell-free supernatants of Gram-pos-
itive bacteria have been reported to stimulate TNF-a pro-
duction from whole human blood and, of 63 strains tested,
supernatants from coagulase-negative staphylococci were
the most effective (37). The S. epidermidis PSMs did not ac-
tivate the HIV-1 LTR in Jurkat T cells, indicating some se-
lectivity for cells of macrophage lineage.
We have concentrated here on the release from S. epider-
midis of three small hydrophobic polypeptides which can915 Mehlin et al.
induce gene activation through an effect on the transcrip-
tion faction NF-kB. S. epidermidis can induce septic shock
in humans (38–46) and a similar shock-like state in animals
(47). Although most attention has focused on the role of
lipoteichoic acid and peptidoglycan as the inducers of cyto-
kine release and shock in this condition, evidence for the
involvement of other factors has been presented. Thus,
S. epidermidis has been reported to be a significant pathogen
in neonatal necrotizing enterocolitis (NEC) (48, 49) and to
be a common pathogen in a milder form of enterocolitis in
infants (50). In one study (48), .90% of the S. epidermidis
isolates from the stools of patients with NEC produced a
toxin resembling delta toxin, and delta toxin was detected
by ELISA in the stools of 11 out of 35 patients with NEC
and toxin-positive staphylococci. Delta toxin was shown to
be enteropathic in infant rats, producing mucosal necrosis
and hemorrhage (48). These findings suggest that coagulase-
negative staphylococci may be enteropathic in humans
through the formation of delta toxin. Delta toxin is produced
by most clinical isolates of coagulase-negative staphylococci,
including strains of S. epidermidis, S. saprophyticus, and S. hemo-
lyticus (51, 52), and a PSMb-like molecule is produced by
S. epidermidis, S. hemolyticus, and S. lugdunensis (25, 26).
Strains of S. aureus also release factors that activate the
HIV-1 LTR in THP-1 cells (3) and induce the release of
TNF-a and IL-1b by human monocytes (53). Essentially,
all strains of S. aureus produce delta toxin; however, it is
not yet known whether a PSMa- or PSMb-equivalent
molecule is produced by this organism. An S. aureus com-
ponent that binds CD14 and induces IL-6 production by
U373 cells and human PBMCs has been described (54, 55).
This factor differs from S. epidermidis PSM in that the active
material distributes into the aqueous phase on hot phenol
extraction. Delta toxin has been shown to induce the re-
lease of TNF-a from human monocytes (56).
In summary, the pathogenesis of Gram-positive septic
shock remains unclear. In 1996, Henderson et al. (2) de-
scribed the issue as follows: “Gram-positive bacteria can
produce a septic shock-like condition and as many people
die each year from Gram-positive as from Gram-negative
sepsis. LPS is obviously a very potent inducer of cytokine
synthesis. Peptidoglycans and teichoic acids are believed to
be the equivalent components, inducing cytokine-induced
shock in patients with Gram-positive sepsis. However,
given the relatively weak cytokine-inducing activity of
peptidoglycan and teichoic acids in the studies described
above, perhaps we have to look at other Gram-positive
bacterial components as the inducers of the shock-like
state.” The staphylococcal PSM is of interest in this regard
in that it is more effective than lipoteichoic acid as an in-
ducer of cytokine release by THP-1 cells or human mono-
cytes. Further, it is normally shed or secreted by the bacte-
ria as indicated by its release into the culture medium on
overnight growth and into the extracellular fluid by vor-
texing of intact organisms. These properties make it a
prime candidate for the initiation of a systemic effect con-
tributing to septic shock in vivo.
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